▶ 調査レポート

口内乾燥症(ドライマウス)治療薬のアジア市場2015-2026

• 英文タイトル:Asia Pacific Xerostomia (Dry Mouth) Therapeutics Market Report (2015-2026) - Market Size, Share, Price, Trend and Forecast

QYResearchが調査・発行した産業分析レポートです。口内乾燥症(ドライマウス)治療薬のアジア市場2015-2026 / Asia Pacific Xerostomia (Dry Mouth) Therapeutics Market Report (2015-2026) - Market Size, Share, Price, Trend and Forecast / MRC1193822資料のイメージです。• レポートコード:MRC1193822
• 出版社/出版日:QYResearch / 2020年2月
• レポート形態:英文、PDF、113ページ
• 納品方法:Eメール(2~3営業日)
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥339,000 (USD3,000)▷ お問い合わせ
  Multi User¥429,400 (USD3,800)▷ お問い合わせ
  Enterprise License¥565,000 (USD5,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要

In 2019, the Asia-Pacific Xerostomia (Dry Mouth) Therapeutics market size was US$ XX million and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX during 2020-2026.
Xerostomia (Dry Mouth) Therapeutics market is segmented by company, region (country), by type, and by application. Players, stakeholders, and other participants in the Asia-Pacific Xerostomia (Dry Mouth) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by type and by application for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Xerostomia (Dry Mouth) Therapeutics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Xerostomia (Dry Mouth) Therapeutics industry.

Segment by Type
 Salagen
 Evoxac
 NeutraSal
 Others

Segment by Application
 Hospital
 Drug Store

Asia-Pacific by Region
 China
 Japan
 South Korea
 India
 Australia
 Taiwan
 Indonesia
 Thailand
 Malaysia

By Company
 GlaxoSmithKline plc
 Church & Dwight, Inc.
 Daiichi Sankyo
 Hikma Pharmaceuticals PLC
 Pendopharm
 Sun Pharmaceuticals Industries Ltd.
 Lupin Pharmaceuticals, Inc.
 Pfizer, Inc.
 Parnell Pharmaceuticals, Inc.
 Acacia Pharm
 Hunan Warrant

レポート目次

1 STUDY COVERAGE
1.1 Xerostomia (Dry Mouth) Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Xerostomia (Dry Mouth) Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Size Growth Rate by Type
1.4.2 Salagen
1.4.3 Evoxac
1.4.4 NeutraSal
1.4.5 Others
1.5 Market by Application
1.5.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Drug Store
1.6 Coronavirus Disease 2019 (Covid-19): Xerostomia (Dry Mouth) Therapeutics Industry Impact
1.6.1 How the Covid-19 is Affecting the Xerostomia (Dry Mouth) Therapeutics Industry
1.6.2 Market Trends and Xerostomia (Dry Mouth) Therapeutics Potential Opportunities in the COVID-19 Landscape
1.6.3 Proposal for Xerostomia (Dry Mouth) Therapeutics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Size Estimates and Forecasts
2.1.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue 2015-2026
2.1.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales 2015-2026
2.2 Xerostomia (Dry Mouth) Therapeutics Market Size by Region: 2020 Versus 2026
3 ASIA-PACIFIC XEROSTOMIA (DRY MOUTH) THERAPEUTICS COMPETITOR LANDSCAPE BY PLAYERS
3.1 Asia-Pacific Top Xerostomia (Dry Mouth) Therapeutics Manufacturers by Sales
3.1.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Manufacturer (2015-2020)
3.1.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Manufacturer (2015-2019)
3.2 Asia-Pacific Top Xerostomia (Dry Mouth) Therapeutics Manufacturers by Revenue
3.2.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue by Manufacturer (2015-2020)
3.2.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue Share by Manufacturer (2015-2020)
3.2.3 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Asia-Pacific Top 10 and Top 5 Companies by Xerostomia (Dry Mouth) Therapeutics Revenue in 2019
3.2.5 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Price by Manufacturer (2015-2020)
3.4 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Manufacturing Base Distribution, Product Type
3.4.1 Xerostomia (Dry Mouth) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Xerostomia (Dry Mouth) Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Xerostomia (Dry Mouth) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Size by Type (2015-2020)
4.1.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Type (2015-2020)
4.1.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue by Type (2015-2020)
4.1.3 Xerostomia (Dry Mouth) Therapeutics Average Selling Price (ASP) by Type (2015-2020)
4.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Size by Application (2015-2020)
5.1.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Application (2015-2020)
5.1.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue by Application (2015-2020)
5.1.3 Xerostomia (Dry Mouth) Therapeutics Price by Application (2015-2020)
5.2 Xerostomia (Dry Mouth) Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Price Forecast by Application (2021-2026)
6 ASIA-PACIFIC BY REGION
6.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Facts & Figures by Region, 2015-2020
6.1.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Region, 2015-2020
6.1.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue by Region, 2015-2020
6.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Market Forecast by Region, 2021-2026
6.2.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales by Region, 2021-2026
6.2.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Revenue by Region, 2021-2026
6.3 Regions (Country) Overview
6.3.1 China
6.3.2 Japan
6.3.3 South Korea
6.3.4 India
6.3.5 Australia
6.3.6 Taiwan
6.3.7 Indonesia
6.3.8 Thailand
6.3.9 Malaysia
6.3.10 Philippines
6.3.11 Vietnam
7 COMPANY PROFILES
7.1 GlaxoSmithKline plc
7.1.1 GlaxoSmithKline plc Corporation Information
7.1.2 GlaxoSmithKline plc Description, Business Overview and Total Revenue
7.1.3 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.1.4 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Products Offered
7.1.5 GlaxoSmithKline plc Recent Development
7.2 Church & Dwight, Inc.
7.2.1 Church & Dwight, Inc. Corporation Information
7.2.2 Church & Dwight, Inc. Description, Business Overview and Total Revenue
7.2.3 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.2.4 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Products Offered
7.2.5 Church & Dwight, Inc. Recent Development
7.3 Daiichi Sankyo
7.3.1 Daiichi Sankyo Corporation Information
7.3.2 Daiichi Sankyo Description, Business Overview and Total Revenue
7.3.3 Daiichi Sankyo Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.3.4 Daiichi Sankyo Xerostomia (Dry Mouth) Therapeutics Products Offered
7.3.5 Daiichi Sankyo Recent Development
7.4 Hikma Pharmaceuticals PLC
7.4.1 Hikma Pharmaceuticals PLC Corporation Information
7.4.2 Hikma Pharmaceuticals PLC Description, Business Overview and Total Revenue
7.4.3 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.4.4 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Products Offered
7.4.5 Hikma Pharmaceuticals PLC Recent Development
7.5 Pendopharm
7.5.1 Pendopharm Corporation Information
7.5.2 Pendopharm Description, Business Overview and Total Revenue
7.5.3 Pendopharm Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.5.4 Pendopharm Xerostomia (Dry Mouth) Therapeutics Products Offered
7.5.5 Pendopharm Recent Development
7.6 Sun Pharmaceuticals Industries Ltd.
7.6.1 Sun Pharmaceuticals Industries Ltd. Corporation Information
7.6.2 Sun Pharmaceuticals Industries Ltd. Description, Business Overview and Total Revenue
7.6.3 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.6.4 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Products Offered
7.6.5 Sun Pharmaceuticals Industries Ltd. Recent Development
7.7 Lupin Pharmaceuticals, Inc.
7.7.1 Lupin Pharmaceuticals, Inc. Corporation Information
7.7.2 Lupin Pharmaceuticals, Inc. Description, Business Overview and Total Revenue
7.7.3 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.7.4 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Products Offered
7.7.5 Lupin Pharmaceuticals, Inc. Recent Development
7.8 Pfizer, Inc.
7.8.1 Pfizer, Inc. Corporation Information
7.8.2 Pfizer, Inc. Description, Business Overview and Total Revenue
7.8.3 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.8.4 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Products Offered
7.8.5 Pfizer, Inc. Recent Development
7.9 Parnell Pharmaceuticals, Inc.
7.9.1 Parnell Pharmaceuticals, Inc. Corporation Information
7.9.2 Parnell Pharmaceuticals, Inc. Description, Business Overview and Total Revenue
7.9.3 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.9.4 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Products Offered
7.9.5 Parnell Pharmaceuticals, Inc. Recent Development
7.10 Acacia Pharm
7.10.1 Acacia Pharm Corporation Information
7.10.2 Acacia Pharm Description, Business Overview and Total Revenue
7.10.3 Acacia Pharm Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.10.4 Acacia Pharm Xerostomia (Dry Mouth) Therapeutics Products Offered
7.10.5 Acacia Pharm Recent Development
7.11 Hunan Warrant
7.11.1 Hunan Warrant Corporation Information
7.11.2 Hunan Warrant Description, Business Overview and Total Revenue
7.11.3 Hunan Warrant Xerostomia (Dry Mouth) Therapeutics Sales, Revenue and Gross Margin (2015-2020)
7.11.4 Hunan Warrant Xerostomia (Dry Mouth) Therapeutics Products Offered
7.11.5 Hunan Warrant Recent Development
8 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
8.1 Market Opportunities and Drivers
8.2 Market Challenges
8.3 Market Risks/Restraints
8.4 Porter’s Five Forces Analysis
8.5 Primary Interviews with Key Xerostomia (Dry Mouth) Therapeutics Players (Opinion Leaders)
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Value Chain Analysis
9.2 Xerostomia (Dry Mouth) Therapeutics Customers
9.3 Sales Channels Analysis
9.3.1 Sales Channels
9.3.2 Distributors
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.2 Data Source
11.2 Author Details
11.3 Disclaimer